Subject(s)
Pneumonia , Toxoplasma , Toxoplasmosis , Zoonoses , Female , Humans , Bronchoscopy , Cell-Free Nucleic Acids/blood , Community-Acquired Infections/blood , Community-Acquired Infections/diagnosis , Community-Acquired Infections/etiology , Community-Acquired Infections/therapy , DNA, Protozoan/blood , DNA, Protozoan/isolation & purification , Hypoxia/blood , Hypoxia/diagnosis , Hypoxia/etiology , Hypoxia/therapy , Immunocompetence , Medical History Taking , Pneumonia/blood , Pneumonia/diagnosis , Pneumonia/etiology , Pneumonia/therapy , Respiratory Insufficiency/blood , Respiratory Insufficiency/diagnosis , Respiratory Insufficiency/therapy , Toxoplasma/isolation & purification , Toxoplasmosis/blood , Toxoplasmosis/diagnosis , Toxoplasmosis/etiology , Toxoplasmosis/therapy , Treatment Outcome , Zoonoses/blood , Zoonoses/diagnosis , Zoonoses/etiology , Zoonoses/therapy , Deer/parasitologyABSTRACT
Las infecciones perinatales son una causa de morbilidad, tanto fetal como neonatal, y que compromete la salud de la mujer embarazada, por lo que su diagnóstico, tratamiento, e intento de eliminación son una prioridad en América Latina y el Caribe. Este documento representa la segunda entrega realizada por expertos en la región dentro de la Sociedad Latinoamericana de Infectología Pediátrica (SLIPE), brindando una mirada actualizada en el manejo de las infecciones congénitas y entrega herramientas para detectar posibles momentos estratégicos de intervención y cambio en el manejo de las infecciones congénitas.
Perinatal infections are a major cause of morbidity and mortality in the fetus, neonate, and the health of the pregnant woman. Diagnosis, treatment, and the search for elimination of these diseases are a priority in Latin America and the Caribbean. This document represents the second delivery by a group of experts in the region inside the Latin-American Society of Pediatric Infectious Diseases (SLIPE), presenting a up-to-date look into the management of congenital infectious diseases and give a tool to detect possible strategic sceneries and a change in the management of congenital infections in our region.
Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/therapy , Arbovirus Infections/congenital , Arbovirus Infections/diagnosis , Arbovirus Infections/therapy , Toxoplasmosis/diagnosis , Toxoplasmosis/therapy , Toxoplasmosis, Congenital , Communicable Diseases , Cytomegalovirus Infections , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/therapy , Dengue , Zika Virus Infection , COVID-19 , Herpes Simplex/congenital , Herpes Simplex/diagnosis , Herpes Simplex/therapyABSTRACT
Cerebral edema frequently develops in the setting of brain infection and can contribute to elevated intracranial pressure, a medical emergency. How excess fluid is cleared from the brain is not well understood. Previous studies have shown that interstitial fluid is transported out of the brain along perivascular channels that collect into the cerebrospinal fluid (CSF)-filled subarachnoid space. CSF is then removed from the central nervous system through venous and lymphatic routes. The current study tested the hypothesis that increasing lymphatic drainage of CSF would promote clearance of cerebral edema fluid during infection with the neurotropic parasite Toxoplasma gondii. Fluorescent microscopy and magnetic resonance imaging was used to show that C57BL/6 mice develop vasogenic edema 4 to 5 weeks after infection with T. gondii. Tracer experiments were used to evaluate how brain infection affects meningeal lymphatic function, which demonstrated a decreased rate in CSF outflow in T. gondii-infected mice. Next, mice were treated with a vascular endothelial growth factor (VEGF)-C-expressing viral vector, which induced meningeal lymphangiogenesis and improved CSF outflow in chronically infected mice. No difference in cerebral edema was observed between mice that received VEGF-C and those that rececived sham treatment. Therefore, although VEGF-C treatment can improve lymphatic outflow in mice infected with T. gondii, this effect does not lead to increased clearance of edema fluid from the brains of these mice.
Subject(s)
Brain Edema , Toxoplasma , Toxoplasmosis , Vascular Endothelial Growth Factor C , Animals , Mice , Brain/pathology , Brain Edema/parasitology , Brain Edema/therapy , Mice, Inbred C57BL , Toxoplasmosis/complications , Toxoplasmosis/therapy , Vascular Endothelial Growth Factor C/therapeutic useABSTRACT
Perinatal and neonatal infections are a significant cause of morbidity and mortality. As such, early recognition and workup when there is clinical concern is essential to supporting affected neonates. This article aims to focus specifically on the effects of toxoplasmosis, rubella, cytomegalovirus, herpes, and other agents (TORCH) infections, discussing epidemiology, diagnostics, and treatment if available. [Pediatr Ann. 2023;52(11):e400-e406.].
Subject(s)
Cytomegalovirus Infections , Herpes Simplex , Pregnancy Complications, Infectious , Rubella , Toxoplasmosis , Pregnancy , Infant, Newborn , Female , Humans , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/drug therapy , Rubella/diagnosis , Rubella/epidemiology , Toxoplasmosis/diagnosis , Toxoplasmosis/therapy , Toxoplasmosis/epidemiologyABSTRACT
BACKGROUND: Toxoplasmosis in hematopoietic stem-cell transplant (HSCT) recipients can be life threatening if not promptly diagnosed and treated. METHODS: We performed a systematic review (PubMed last search March 29, 2020) of toxoplasmosis among HSCT recipients and calculated the toxoplasmosis prevalence across studies. We also created a compilation list of brain imaging, chest imaging, and autopsy findings of toxoplasmosis among HSCT recipients. RESULTS: We identified 46 eligible studies (47 datasets) with 399 toxoplasmosis cases among 38 751 HSCT recipients. There was large heterogeneity in the reported toxoplasmosis prevalence across studies, thus formal meta-analysis was not attempted. The median toxoplasmosis prevalence among 38 751 HSCT recipients was 2.14% (range 0%-66.67%). Data on toxoplasmosis among at-risk R+HSCT recipients were more limited (25 studies; 2404 R+HSCT recipients [6.2% of all HSCT recipients]), although the median number of R+HSCT recipients was 56.79% across all HSCT recipients. The median toxoplasmosis prevalence across studies among 2404 R+HSCT was 7.51% (range 0%-80%) versus 0% (range 0%-1.23%) among 7438 R-HSCT. There were limited data to allow meaningful analyses of toxoplasmosis prevalence according to prophylaxis status of R+HSCT recipients. CONCLUSIONS: Toxoplasmosis prevalence among HSCT recipients is underestimated. The majority of studies report toxoplasmosis prevalence among all HSCT recipients rather than only among the at-risk R+HSCT recipients. In fact, the median toxoplasmosis prevalence among all R+//R- HSCT recipients is 3.5-fold lower compared with the prevalence among only the at-risk R+HSCT recipients and the median prevalence among R+HSCT recipients is 7.51-fold higher than among R-HSCT recipients. The imaging findings of toxoplasmosis among HSCT recipients can be atypical. High index of suspicion is needed in R+HSCT recipients with fever, pneumonia, or encephalitis.
Subject(s)
Hematopoietic Stem Cell Transplantation , Toxoplasmosis , Autopsy , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Prevalence , Toxoplasmosis/diagnosis , Toxoplasmosis/epidemiology , Toxoplasmosis/therapy , Transplant RecipientsABSTRACT
BACKGROUND: Toxoplasma gondii is the global protozoa that could cause contamination in warm-blooded animals and is considered among the opportunistic pathogens in immunocompromised patients. Among the people at risk, toxoplasmosis infection can lead to the incidence of severe clinical manifestations, encephalitis, chorioretinitis, and even death. PURPOSE: The present research is focused on the new research for the treatment of toxoplasmosis parasitic disease using medicinal herbs. METHODS: The search was performed in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar up from 2010 to December 2019. Studies in any language were entered in the searching step if they had an English abstract. The words and terms were used as a syntax with specific tags of each database. RESULTS: Out of 1832 studies, 36 were eligible to be reviewed. The findings showed that 17 studies (47%) were performed in vitro, 14 studies (39%) in vivo, and 5 studies (14%) both in vivo and in vitro. CONCLUSION: The studies showed that the plant extracts can be a good alternative in reducing the toxoplasmosis effects in the host and the herbal extracts can be used to produce natural product-based drugs affecting toxoplasmosis with fewer side-effects than synthetic drugs.
Subject(s)
Plants, Medicinal , Toxoplasma , Toxoplasmosis , Animals , Humans , Immunocompromised Host , Plant Extracts , Toxoplasmosis/therapyABSTRACT
Toxoplasma gondii (T. gondii), an obligatory intracellular parasite, is the etiologic agent of toxoplasmosis. Dihydrofolate reductase-thymidylate synthase (DHFR-TS) is one of the most important enzymes in toxoplasma folic acid cycle. Due to the emergence of resistance in RH strain of T. gondii against pyrimethamine that acts via DHFR-TS inhibition and also the crucial role of small interference RNA (siRNA) technology in gene silencing, we aimed to use siRNA to knock down DHFR-TS gene expression in T. gondii as a therapeutic target against toxoplasmosis in a mouse model. Based on the DHFR-TS gene sequence, siRNA was designed. The siRNAs were transfected into the parasites by electroporation. Total RNA was extracted using RNX-Plus kit. The viability of parasite was assessed by methylthiazole tetrazolium (MTT). The survival time of mice challenged with siRNA-treated T.gondii were compared to the control group infected with the same amount of wild-type tachyzoites. The viability of siRNA-embedded parasites was 70.7% (29.3% decreased) compared to the wild-type parasite as control (P = 0.0001). The transcription level of siRNA-transfected parasites was reduced to 17.4% (82.6% inhibition) (P = 0.016). The in vivo assessment showed that the mean survival time of the mice inoculated with modified parasites was increased about 2 days after the death of all mice in the control group. The designed siRNAs in the current study were able to silence the DHFR-TS gene efficiently. This silencing led to a decrease in viability of the parasites and an increase in the survival time of the parasites-treated mice.
Subject(s)
Multienzyme Complexes/antagonists & inhibitors , RNA, Small Interfering/genetics , Thymidylate Synthase/antagonists & inhibitors , Toxoplasma/enzymology , Toxoplasmosis/therapy , Animals , Mice , Multienzyme Complexes/genetics , Pyrimethamine/pharmacology , Tetrahydrofolate Dehydrogenase/genetics , Thymidylate Synthase/genetics , Toxoplasma/drug effectsSubject(s)
Adoptive Transfer/adverse effects , Lymphohistiocytosis, Hemophagocytic , Lymphoma, Large B-Cell, Diffuse/therapy , Toxoplasmosis , Humans , Lymphohistiocytosis, Hemophagocytic/etiology , Lymphohistiocytosis, Hemophagocytic/therapy , Male , Middle Aged , Toxoplasmosis/etiology , Toxoplasmosis/therapyABSTRACT
Several infections have unique consequences or considerations in pregnancy. Some common infections such as urinary tract infections, influenza, sexually transmitted diseases, and vaginitis affect pregnant women differently than the general population, can cause pregnancy complications, and require treatments that are safe in pregnancy. Infections such as hepatitis B and C and human immunodeficiency virus can be transmitted vertically and therefore management focuses on decreasing perinatal transmission. Certain infections can be transmitted in utero and cause congenital infections. Classically, these were grouped together as the TORCH infections, although now several others, including varicella virus, parvovirus, and Zika virus, have also been recognized.
Subject(s)
Pregnancy Complications, Infectious/diagnosis , Chlamydia Infections/complications , Chlamydia Infections/diagnosis , Chlamydia Infections/therapy , Female , Gonorrhea/complications , Gonorrhea/diagnosis , Gonorrhea/therapy , HIV Infections/complications , HIV Infections/diagnosis , HIV Infections/therapy , Humans , Infectious Disease Transmission, Vertical , Influenza, Human/complications , Influenza, Human/diagnosis , Influenza, Human/therapy , Pregnancy , Pregnancy Complications, Infectious/therapy , Syphilis/complications , Syphilis/diagnosis , Syphilis/therapy , Toxoplasmosis/complications , Toxoplasmosis/diagnosis , Toxoplasmosis/therapy , Urinary Tract Infections/complications , Urinary Tract Infections/diagnosis , Urinary Tract Infections/therapy , Vaginitis/complications , Vaginitis/diagnosis , Vaginitis/therapy , Virus Diseases/complications , Virus Diseases/diagnosis , Virus Diseases/therapyABSTRACT
INTRODUCTION: Toxoplasmosis is a life-threatening parasitic disease for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. The risk of toxoplasmosis in transplant patients mainly depends on the degree of immunosuppression, the tropism of Toxoplasma gondii for the grafted tissue, and the seroprevalence in the general population. Although transplant recipients with toxoplasmosis have a high mortality rate, there are neither well-defined recommendations nor a consensus for the management of this disease in these patients. Areas covered. This review focuses on the management of toxoplasmosis in transplant recipients and discusses the various strategies for diagnosis, prevention, treatment, and follow-up in clinical practice. The literature search was conducted on publications in English and French using the search terms 'Toxoplasma gondii,' 'organ transplant,' and 'transplant recipients.' Expert commentary. The diagnosis of toxoplasmosis has greatly improved over the last two decades, but it is still a fatal illness. Non-specificity of the symptoms, resulting in a delay before diagnosis, and therapeutic failure are the main causes of death. The development of active treatments against cysts is one of the current challenges that will considerably improve the management of toxoplasmosis in transplant recipients by clearing chronic infection to avoid T. gondii reactivation.
Subject(s)
Immunocompromised Host , Toxoplasmosis/therapy , Transplant Recipients , Animals , Antiprotozoal Agents/administration & dosage , Hematopoietic Stem Cell Transplantation/methods , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Organ Transplantation/methods , Risk Factors , Toxoplasma/isolation & purification , Toxoplasmosis/diagnosis , Toxoplasmosis/etiologySubject(s)
Toxoplasmosis , Centers for Disease Control and Prevention, U.S. , Cooking , Foodborne Diseases/parasitology , Foodborne Diseases/prevention & control , Humans , Mass Screening , Patient Education as Topic , Toxoplasmosis/diagnosis , Toxoplasmosis/etiology , Toxoplasmosis/prevention & control , Toxoplasmosis/therapy , United StatesABSTRACT
Toxoplasma gondii is an obligate intracellular protozoan that can invade all eukaryotic cells and infect all warm-blood animals, causing the important zoonosis toxoplasmosis. Invasion of host cells is the key step necessary for T. gondii to complete its life cycle and microneme proteins play an important role in attachment and invasion of host cells. Microneme protein 16 (TgMIC16) is a new protective protein in T. gondii and belongs to transmembrane microneme proteins (TM-MIC). The TM-MICs are released onto the parasite's surface as complexes capable of interacting with host cell receptors. In the present study, we expressed the TgMIC16 protein on the surface of Saccharomyce cerevisiae (pCTCON2-TgMIC16/EBY100) and evaluated it as a potential vaccine for BALB/c mice against challenge infection with the RH strain of T. gondii. We immunized BALB/c mice both orally and intraperitoneally. After three immunizations, the immune response was evaluated by measuring antibody levels, lymphocyte proliferative responses, percentages of CD4+ and CD8+ T lymphocytes, cytokine production, and the survival times of challenged mice. The results showed that the pCTCON2-TgMIC16/EBY100 vaccine stimulated humoral and cellular immune responses. In addition, mice immunized with the pCTCON2-TgMIC16/EBY100 vaccine showed increased survival times compared with non-immunized controls. In summary, TgMIC16 displayed on the cell surface of S. cerevisiae could be used as potential vaccine against toxoplasmosis.
Subject(s)
Antibodies, Protozoan/immunology , Immunity, Cellular/immunology , Immunity, Humoral/immunology , Protozoan Proteins/immunology , Protozoan Vaccines/immunology , Toxoplasma/immunology , Toxoplasmosis/prevention & control , Administration, Oral , Animals , Antibodies, Protozoan/blood , Female , Humans , Immunization , Injections, Intraperitoneal , Male , Mice , Mice, Inbred BALB C , Protozoan Proteins/genetics , Protozoan Vaccines/therapeutic use , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/immunology , Toxoplasmosis/therapy , Vaccines, Synthetic/immunology , Vaccines, Synthetic/therapeutic useABSTRACT
The purpose of our study was to report the particularities of the management of toxoplasmosis seroconversion cases occurred during the third trimester of pregnancy and diagnosed in the Institute Pasteur of Tunis. The study was conducted in the Laboratory of Parasitology-Mycology of the Institute Pasteur of Tunis between January 2005 and December 2017. A total of 27 cases of toxoplasmosis seroconversion during the third trimester were included. Prenatal diagnosis was performed in five cases. PCR was positive in one case. Pyrimethamine-sulfadoxine was prescribed in one case with positive PCR and in another case as soon as maternal infection was confirmed. Spiramycine was prescribed in 24 cases for the duration of the pregnancy. One woman did not take any treatment because seroconversion was diagnosed just before delivery. Twenty newborns had congenital toxoplasmosis: 19 cases were diagnosed by serology and one case was diagnosed after amniocentesis. Two newborns (10%) were symptomatic at birth. All the newborns had neither clinical nor radiological signs during the follow-up.
L'objectif de notre travail était de rapporter les particularités de la prise en charge d'une série de cas de séroconversion toxoplasmique du troisième trimestre de grossesse diagnostiquée à l'institut Pasteur de Tunis. Il s'agit d'une étude rétrospective colligée au laboratoire de parasitologie-mycologie de l'institut Pasteur de Tunis entre janvier 2005 et décembre 2017, incluant 27 femmes enceintes ayant présenté une séroconversion toxoplasmique au cours du troisième trimestre de la grossesse diagnostiquée au cours de leurs suivis sérologiques. Cinq femmes ont bénéficié d'un diagnostic anténatal. La PCR (polymerase chain reaction) s'est révélée positive dans un seul cas. Deux femmes ont été mises sous pyriméthamine-sulfadoxine dont une avait une PCR positive. La spiramycine a été instituée chez 24 femmes jusqu'à l'accouchement. Une femme n'a reçu aucun traitement, la séroconversion ayant été diagnostiquée la veille de l'accouchement. Le diagnostic de la toxoplasmose congénitale a été retenu chez 20 nouveau-nés (74 %) dont un en anténatal et 19 à la naissance. Deux étaient symptomatiques (10 %) à la naissance. Aucune manifestation clinique ou radiologique n'a été observée au cours de leurs suivis.
Subject(s)
Pregnancy Complications, Infectious/therapy , Pregnancy Trimester, Third , Seroconversion/physiology , Toxoplasmosis, Congenital/prevention & control , Toxoplasmosis/therapy , Adult , Drug Combinations , Female , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Infectious Disease Transmission, Vertical/statistics & numerical data , Male , Pregnancy , Pregnancy Complications, Infectious/blood , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/epidemiology , Pregnancy Trimester, Third/blood , Pregnancy Trimester, Third/immunology , Prenatal Diagnosis , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Toxoplasmosis/blood , Toxoplasmosis/diagnosis , Toxoplasmosis/epidemiology , Toxoplasmosis, Congenital/blood , Toxoplasmosis, Congenital/diagnosis , Toxoplasmosis, Congenital/epidemiology , Tunisia/epidemiology , Young AdultABSTRACT
Toxoplasmosis is mostly associated with other intestinal parasitic infections especially Giardia due to shared mode of peroral infection. Toxoplasma and Giardia induce a strong T-helper 1- immune response. Our aim was to induce a protective immune response that results in significant impact on intestinal and extra-intestinal phases of Toxoplasma infection. This study was conducted in experimental animals and assessment of Giardia cyst extract effect on Toxoplasma infection was investigated by histopathological examination of small intestine and brain, Toxoplasma cyst count and iNOS staining of the brain, measurement of IFN-γ and TGF-ß in intestinal tissues. Results showed that the brain Toxoplasma cyst number was decreased in mice infected with Toxoplasma then received Giardia cyst extract as compared to mice infected with Toxoplasma only. This effect was produced because Giardia cyst extract augmented the immune response to Toxoplasma infection as evidenced by severe inflammatory reaction in the intestinal and brain tissues, increased levels of IFN-γ and TGF-ß in intestinal tissues and strong iNOS staining of the brain. In conclusion, Giardia cyst extract generated a protective response against T. gondii infection. Therefore, Giardia antigen will be a suitable candidate for further researches as an immunomodulatory agent against Toxoplasma infection.
Subject(s)
Antigens, Protozoan/immunology , Giardia/immunology , Giardiasis/immunology , Toxoplasma/immunology , Toxoplasmosis, Animal/immunology , Toxoplasmosis/therapy , Animals , Brain/parasitology , Female , Giardiasis/parasitology , Inflammation/immunology , Inflammation/parasitology , Interferon-gamma/immunology , Intestine, Small/immunology , Mice , Nitric Oxide Synthase Type II/analysis , Th1 Cells/immunology , Toxoplasmosis/immunology , Transforming Growth Factor beta/immunologyABSTRACT
INTRODUCTION: Gestational toxoplasmosis is frequent and severe. There is still debate about the benefits of treatment against ocular manifestations in the newborn. Spiramycin treatment is used for this purpose, unfortunately prenatal diagnosis is sometimes delayed and pregnant women are not treated. OBJECTIVE: To describe the relationship between treatment with spiramycin during pregnancy in mothers with gestational toxoplasmosis and development of ocular toxoplasmosis in newborns. MATERIALS AND METHODS: We conducted a descriptive study of a case series. We evaluated a prospective cohort of patients diagnosed with gestational toxoplasmosis during three years at the Retinology Service at the Clínica Universitaria Bolivariana in Medellín. RESULTS: Gestational toxoplasmosis was found in 23 mothers; 15 (65%) were treated during pregnancy with 3 g per day of spiramycin, eight (35%) patients were untreated. In the treated group just one newborn developed ocular toxoplasmosis (6.6%), in contrast with five (62.5%) of the eight patients who did not receive treatment. These results suggest that pregnancy treatment reduces the relative risk of ocular toxoplasmosis in the newborn by 96% (95% CI: 33 - 100%). Only two (14%) of the patients who were evaluated, had nervous system involvement related to toxoplasmosis in CT scan or cerebral ultrasound. These two patients also developed ocular pathology and were diagnosed at the time of birth, so they did not received antenatal treatment. CONCLUSIONS: A protective effect was found against the ocular involvement in patients whose mother received treatment with spiramycin (OR=0.04;95% CI: 0.00-0.67), p<0.01 (Fisher's Exact Test).
Subject(s)
Spiramycin/pharmacology , Toxoplasmosis, Congenital/drug therapy , Toxoplasmosis/epidemiology , Colombia , Female , Humans , Infant, Newborn , Pregnancy , Prenatal Diagnosis , Prospective Studies , Spiramycin/chemistry , Toxoplasmosis/genetics , Toxoplasmosis/prevention & control , Toxoplasmosis/therapy , Toxoplasmosis, Congenital/diagnosis , Toxoplasmosis, Congenital/epidemiology , Toxoplasmosis, Congenital/prevention & controlABSTRACT
Existen numerosas infecciones bacterianas, virales y parasitarias que pueden transmitirse desde la madre al feto o recién nacido (RN) y que significan un riesgo para él. El acrónimo TORCH se utiliza en forma universal para caracterizar a aquel feto o RN que presenta un cuadro clínico compatible con una infección congénita y que permite un enfrentamiento racional, tanto diagnóstico como terapéutico. El concepto tradicional de realizar un "test de TORCH" sin consideraciones específicas a cada paciente, hoy en día se considera no adecuado y ha sido reemplazado por exámenes específicos para patógenos específicos bajo circunstancias bien definidas. El presente documento revisa las características generales, epidemiológicas, patogénicas, diagnósticas y terapéuticas de los patógenos más frecuentemente involucrados en el estudio de pacientes con sospecha de TORCH.
There is a lot of bacterial, viral or parasite infections who are able to be transmitted vertically from the mother to the fetus or newborn which implicates an enormous risk for it. The TORCH acronym is used universally to refer to a fetus or newborn which presents clinical features compatible with a vertically acquired infection and allows a rational diagnostic and therapeutic approach. The traditional "TORCH test" is nowadays considered not appropriate and it has been replaced for specific test for specific pathogens under well defined circumstances. The present document reviews the general characteristics, epidemiology, pathogenesis, diagnostic and therapeutic options for the most frequently involved pathogens in the fetus or newborn with TORCH suspicion.
Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Toxoplasmosis/diagnosis , Chagas Disease/epidemiology , Cytomegalovirus Infections/congenital , Chile , Toxoplasmosis/therapy , Toxoplasmosis/epidemiology , Neonatal Screening/methods , Practice Guideline , Chagas Disease/therapy , Cytomegalovirus Infections/diagnosis , Infectious Disease Transmission, Vertical , Herpes Simplex/congenital , Herpes Simplex/epidemiology , Measles/congenital , Measles/epidemiologyABSTRACT
Resumen Introducción. La toxoplasmosis de la gestación es frecuente y grave. Hasta ahora no hay consenso sobre la utilidad del tratamiento para prevenir complicaciones oculares en el neonato. En la actualidad, uno de los medicamentos utilizados en las madres diagnosticadas es la espiramicina oral. Infortunadamente, en algunas mujeres gestantes no se hace el diagnóstico prenatal y, por esta u otras razones, no reciben el tratamiento. Objetivo. Describir la relación entre el tratamiento con espiramicina durante el embarazo en madres con toxoplasmosis de la gestación y la presentación de toxoplasmosis ocular en los recién nacidos. Materiales y métodos. Se llevó a cabo un estudio observacional descriptivo de serie de casos. Se evaluó una serie prospectiva de pacientes con toxoplasmosis de la gestación durante tres años de seguimiento en el Servicio de Retinología de la Clínica Universitaria Bolivariana de Medellín. Resultados. Se registraron 23 madres con diagnóstico de toxoplasmosis de la gestación. Quince de ellas (65 %) recibieron durante la gestación tratamiento con espiramicina en dosis de 3 g al día; uno de los neonatos (6,6 %) presentó toxoplasmosis ocular. De las ocho (35 %) pacientes que no recibieron tratamiento, cinco (62,5 %) tuvieron hijos con compromiso ocular por toxoplasma. La razón de momios (odds ratio, OR) del efecto protector contra dicho compromiso en los pacientes cuyas madres recibieron tratamiento fue de 0,04 (IC95% 0,00-0,67), con valor de p menor de 0,01 en la prueba exacta de Fisher. Solo se evidenció compromiso del sistema nervioso central por toxoplasmosis mediante las imágenes de tomografía o ecografía cerebral en dos (14 %) pacientes de las 14 en quienes se hicieron estos estudios. Los dos pacientes presentaron, además, compromiso ocular; ambos fueron diagnosticados en el momento del nacimiento y sus madres no habían recibido tratamiento prenatal. Conclusiones. Estos resultados evidencian que el tratamiento con espiramicina durante el embarazo en la toxoplasmosis de la gestación redujo en 96 % (IC95% 33-100 %) el riesgo relativo de presentar la enfermedad en el recién nacido.
Abstrat Introduction: Gestational toxoplasmosis is frequent and severe. There is still debate about the benefits of treatment against ocular manifestations in the newborn. Spiramycin treatment is used for this purpose, unfortunately prenatal diagnosis is sometimes delayed and pregnant women are not treated. Objective: To describe the relationship between treatment with spiramycin during pregnancy in mothers with gestational toxoplasmosis and development of ocular toxoplasmosis in newborns. Materials and methods: We conducted a descriptive study of a case series. We evaluated a prospective cohort of patients diagnosed with gestational toxoplasmosis during three years at the Retinology Service at the Clínica Universitaria Bolivariana in Medellín. Results: Gestational toxoplasmosis was found in 23 mothers; 15 (65%) were treated during pregnancy with 3 g per day of spiramycin, eight (35%) patients were untreated. In the treated group just one newborn developed ocular toxoplasmosis (6.6%), in contrast with five (62.5%) of the eight patients who did not receive treatment. These results suggest that pregnancy treatment reduces the relative risk of ocular toxoplasmosis in the newborn by 96% (95% CI: 33 - 100%). Only two (14%) of the patients who were evaluated, had nervous system involvement related to toxoplasmosis in CT scan or cerebral ultrasound. These two patients also developed ocular pathology and were diagnosed at the time of birth, so they did not received antenatal treatment. Conclusions: A protective effect was found against the ocular involvement in patients whose mother received treatment with spiramycin (OR=0.04;95% CI: 0.00-0.67), p<0.01 (Fisher's Exact Test).